

21
B4

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 177 789 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
06.02.2002 Bulletin 2002/06

(51) Int Cl.7: A61K 31/20, A61P 3/04,
A61P 3/06, A61P 3/10

(21) Application number: 01118230.0

(22) Date of filing: 30.07.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 04.08.2000 EP 00116848

(71) Applicant: Roche Vitamins AG
4070 Basel (CH)

(72) Inventors:
• Fluehmann, Beat
8055 Zuerich (CH)

• Heim, Manuel
79098 Freiburg (DE)
• Hunziker, Willi
4312 Magden (CH)
• Weber, Peter
79429 Malsburg-Marzell (DE)

(74) Representative: Müller, Ingrid, Dr. et al
Grenzacherstrasse 124
CH-4070 Basel (CH)

(54) Use of phytanic acid for the treatment of diabetes

(57) This invention relates to a novel method for the treatment or prevention of preferably non-insulin dependent (NIDDM or so-called Type II) diabetes mellitus, or other conditions associated with impaired glucose tol-

erance such as obesity, and in particular to the use of phytanic acid derivatives for the said treatment or prevention.

EP 1 177 789 A2

Description

[0001] The present invention relates to phytanic acid derivatives and their use for the treatment or the prevention of diabetes mellitus.

5 [0002] This invention relates to a novel method for the treatment and / or prevention of preferably non-insulin dependent (NIDDM or so-called Type II) diabetes mellitus, and in particular to the use of phytanic acid derivatives for the said treatment or prevention.

10 [0003] NIDDM is the form of diabetes mellitus which occurs predominantly in adults in whom adequate production of insulin is available for use, yet a defect exists in insulin-mediated utilization and metabolism of glucose in peripheral tissues. Overt NIDDM is characterized by three major metabolic abnormalities: elevated serum glucose levels, resistance to insulin-mediated glucose disposal, and overproduction of glucose by the liver.

15 [0004] Previous mechanisms of action of oral antidiabetics such as the generally used sulfonyl ureas are primarily based on an increased release of insulin from the beta cells of the pancreas, a mechanism which in the long term may lead to accelerated exhaustion of the endogenous production of insulin in diabetics. The modern view of the pathobi-
ochemistry of adultonset diabetes mellitus therefore emphasizes the need to treat the peripheral insulin resistance that is present in this case.

20 [0005] The human diet contains phytol, a metabolite of the chlorophyll molecule. Phytol is metabolized to phytanic acid and phytanic acid (see Figure 6). Intestinal absorption of phytol from dietary chlorophyll was shown to be minimal (Baxter, J. H. & Steinberg, D. (1967) Absorption of phytol from dietary chlorophyll in the rat, *J Lipid Res.* 8, 615-20; Baxter, J. H. (1968) Absorption of chlorophyll phytol in normal man and in patients with Refsum's disease, *J Lipid Res.* 9, 636-41).

25 [0006] In rats, phytol is much less well adsorbed than phytanic acid (Baxter, J. H., Steinberg, D., Mize, C. E. & Avigan, J. (1967) Absorption and metabolism of uniformly ¹⁴C-labeled phytol and phytanic acid by the intestine of the rat studied with thoracic duct cannulation, *Biochim Biophys Acta.* 137, 277-90).

30 [0007] In humans, dairy products and ruminant fats in the human diet are the major sources of phytanic acid. A normal diet contains 50 - 100 mg of phytanic acid per day (Steinberg. (1995) Refsum Disease in the Metabolic and Molecular Bases of Inherited Metabolic Disorders pp. 2351-2369, McGraw-Hill, New York). Phytanic- and phytanic acid levels in normal human serum were 2 µM and 6 µM (Avigan, J. (1966) The presence of phytanic acid in normal human and animal plasma, *Biochim Biophys Acta.* 116, 391-4). Phytanic acid may be elevated 50-fold in patients with here-
dopathia atactica polyneuritiformis (Refsum's disease), an inherited metabolic disorder characterized by an α-hydrox-
ylase gene defect that prevents the conversion of phytanic acid to pristanic acid (Verhoeven, N. M., Wanders, R. J., Poll-The, B. T., Saudubray, J. M. & Jakobs, C. (1998) The metabolism of phytanic acid and pristanic acid in man: a review, *J Inherit Metab Dis.* 21, 697-728).

35 [0008] In adult mice fed a 0.5% phytol diet for 21 days a 40% decrease in the triglyceride serum levels was noted. However cholesterol serum levels remained unaffected (Van den Branden, C., Vamecq, J., Wybo, I. & Roels, F. (1986) Phytol and peroxisome proliferation, *Pediatr Res.* 20, 411-5). Moreover, expression of enzymes, known to be involved in beta-oxidation and regulated by peroxisome proliferator-activated receptor (PPAR) was observed to be up regulated. Recently it was shown that phytanic acid is a 9-cis-retinoic acid receptor (RXR) as well as a PPAR α ligand (Kitareewan, S., Burka, L. T., Tomer, K. B., Parker, C. E., Deterding, L. J., Stevens, R. D., Forman, B. M., Mais, D. E., Heyman, R. A., McMorris, T. & Weinberger, C. (1996) Phytol metabolites are circulating dietary factors that activate the nuclear receptor RXR, *Molecular Biology of the Cell.* 7, 1153-66.; Lemotte, P. K., Keidel, S. & Apfel, C. M. (1996) Phytanic acid is a retinoid X receptor ligand, *Eur J Biochem.* 236, 328-33; Wolfrum, C., Ellinghaus, P., Fobker, M., Seedorf, U., Assmann, G., Borchers, T. & Spener, F. (1999) Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein, *J Lipid Res.* 40, 708-14.; Ellinghaus, P., Wolfrum, C., Assmann, G., Spener, F. & Seedorf, U. (1999) Phytanic acid activates the peroxisome proliferator-activated receptor alpha (PPAR α) in sterol carrier protein 2-/ sterol carrier protein x-deficient mice, *J Biol Chem.* 274, 2766-72 and WO 97/09039).

40 [0009] RXR receptor binding and transcriptional effects were observed with EC50 and IC50 of 3 µM and 2.3 µM respectively. The Kd-value for phytanic acid as PPAR α ligand is reported as 10 nM (Ellinghaus et al., supra). In contrast to the ability of 9-cis-retinoic acid to activate both RXR and all-trans-retinoic acid receptor (RAR) (EC50 2.5 nM and 13 nM), phytanic acid activity is restricted to RXR receptors. Activation of both PPAR α and RXR by phytanic acid and the specificity with respect to the retinoid receptors may lead to a distinct pattern of gene induction as opposed to the pattern observed in other fatty acids.

45 [0010] Liver is second to skeletal muscle as the most important tissue in glucose metabolism and therefore is an important regulator of glucose level in plasma. It is well known that activation of PPAR γ by the antidiabetic thiazolidinediones such as troglitazone rosiglitazone and pioglitazone leads to restored insulin sensitivity in case of diabetes mellitus type II (Berger, J., Bailey, P., Biswas, C., Cullinan, C. A., Doeber, T. W., Hayes, N. S., Saperstein, R., Smith, R. G. & Leibowitz, M. D. (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice, *Endocrinology.* 137,

4189-95; Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M. & Kliewer, S. A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR γ), J Biol Chem. 270, 12953-6.12, 13). Expression of PPAR α as well as PPAR γ was shown in liver of rodents and humans (Mukherjee, R., Jow, L., Croston, G. E. & Paterniti, J. R., Jr. (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR γ 2 versus PPAR γ 1 and activation with retinoid X receptor agonists and antagonists, J Biol Chem. 272, 8071-6.; Lemberger, T., Braissant, O., Juge-Aubry, C., Keller, H., Saladin, R., Staels, B., Auwerx, J., Burger, A. G., Meier, C. A. & Wahli, W. (1996) PPAR tissue distribution and interactions with other hormone-signaling pathways, Ann N Y Acad Sci. 804, 231-51; Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L. & Johnson, E. F. (1998) Peroxisome proliferator activated receptor-alpha expression in human liver, Mol Pharmacol. 53, 14-22.; Vidal-Puig, A. J., Considine, R. V., Jimenez-Linan, M., Werman, A., Pories, W. J., Caro, J. F. & Flier, J. S. (1997) Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids, J Clin Invest. 99, 2416-22).

[0011] Phytanic acid was described as a ligand for both RXR and PPAR α (Kitareewan, et al. (supra); Lemotte et al. (supra); Ellinghaus et al (supra) and WO 97/09039). Decaux et al. (Decaux, J. F., Juanes, M., Bossard, P. & Girard, J. (1997) Effects of triiodothyronine and retinoic acid on glucokinase gene expression in neonatal rat hepatocytes, Mol Cell Endocrinol. 130, 61-7) demonstrated in primary cultures of rat hepatocytes, an up-regulation of glucokinase mRNA by retinoic acid. Together with the finding that the phosphoenolpyruvate carboxykinase (PEPCK) gene is regulated among other responsive elements by a PPAR responsive element (PPRE) (Juge-Aubry, C., Pernin, A., Favez, T., Burger, A. G., Wahli, W., Meier, C. A. & Desvergne, B. (1997) DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5'-flanking region, J Biol Chem. 272, 25252-9; Hanson, R. W. & Reshef, L. (1997) Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression, Annu Rev Biochem. 66, 581-611), a RXR/PPAR mediated up-regulation of the glucose influx in hepatocytes could be a reasonable explanation. PPAR forms permissive heterodimers with RXR, meaning that either partner can regulate the transcriptional activity by interacting with its own ligand. Co-treatment of the cells with ligands for PPAR as well as RXR results in an additive effect. Moreover it was shown that ligands selective for RXR could activate PPRE driven reporter genes (Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A. & Evans, R. M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors, Nature. 358, 771-4; Gearing, K. L., Gottlicher, M., Teboul, M., Widmark, E. & Gustafsson, J. A. (1993) Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor, Proc Natl Acad Sci U S A. 90, 1440-4; Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K. & Wahli, W. (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers, Proc Natl Acad Sci U S A. 90, 2160-4).

[0012] *In vivo* sensitization to insulin was observed in diabetic and obese mice in response to RXR agonists, comparable to the effects known from the thiazolidinediones (Mukherjee, R., Davies, P. J., Crombie, D. L., Bischoff, E. D., Cesario, R. M., Jow, L., Hamann, L. G., Boehm, M. F., Mondon, C. E., Nadzan, A. M., Paterniti, J. R., Jr. & Heyman, R. A. (1997) Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists, Nature. 386, 407-10).

[0013] However, there is no indication in the prior art that phytanic acid derivatives, preferably phytanic acid, would have a beneficial effect on NIDDM itself.

[0014] Surprisingly, experiments showed that phytanic acid derivatives, preferably phytanic acid, can increase and stimulate the transcription of the genes for glucose transporters and glucokinase resulting in increased glucose uptake in hepatocytes.

[0015] Moreover, phytanic acid derivatives normalize and increase the glucose level without a concomitant risk of hypoglycemia and is thus excellently suited for the treatment or prevention of diabetes mellitus.

[0016] An object of the present invention is therefore a novel method for the treatment or prevention of preferably NIDDM.

[0017] This is achieved by the use of phytanic acid derivatives for the treatment or prevention of diabetes mellitus, preferably diabetes mellitus type II *per se*. In a particular embodiment the use of phytanic acid as such is preferred.

[0018] The present invention demonstrates that glucose uptake in primary cultures of hepatocytes is markedly induced by levels of phytanic acid derivatives one order of magnitude higher than serum concentration. The enzymes involved in glucose uptake are the various members of the facilitative glucose transporter (GLUT) family, GLUT-1, GLUT-2, and GLUT-4 (see (Olson, A. L. & Pessin, J. E. (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family, Annu Rev Nutr. 16, 235-56)) and glucokinase. The up regulation of the mRNA levels of GLUT-1 and GLUT-2 observed in the present invention are accompanied by an increased 2-deoxy-D-glucose uptake. The liver type glucose transporter GLUT-2 is distinguished from the other GLUT isoforms by being a low-affinity glucose transporter with a high turnover rate (Gould, G. W., Thomas, H. M., Jess, T. J. & Bell, G. I. (1991) Expression of human glucose transporters in Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms, Biochemistry. 30, 5139-45).

[0019] The presence of a low affinity glucose transporter ensures that in liver, glucose flux is directly proportional to

the plasma glucose concentration. Moreover, in hepatocytes GLUT-2 is coupled with the regulated phosphorylating activity provided by the glucokinase. Thus, during states of glycogen synthesis, glucokinase is up regulated and can increase the formation of intracellular glucose-6-phosphate, maintaining a low intracellular concentration of free glucose (Magnuson, M. A., Andreone, T. L., Printz, R. L., Koch, S. & Granner, D. K. (1989) Rat glucokinase gene: structure and regulation by insulin, Proc Natl Acad Sci U S A. 86, 4838-42).

[0020] Therefore, a further object of the present invention relates to phytanic acid derivatives which are able to serve as a modulator, having the activity to induce or to stimulate the gene expression of the above mentioned enzymes, and to provide an enhanced serum glucose clearance by improved liver glucose uptake.

[0021] As used herein, the term "phytanic acid derivatives" includes phytanic acid as such or its precursors (as depicted in Figure 6), wherein phytanic acid as such and phytol as such are preferred. Furthermore, derivatives thereof such as, but not limited to, hydroxy-phytanic acid or hydroxy-phytic acid, especially 2-hydroxy-phytanic acid or 2-hydroxy-phytic ester, hydroxy-phytanic esters, phytanic amides, phytanic amides, hydroxy-phytanic amides, hydroxy-phytanic amides, hydrocarbon esters, phospholipid esters and triacylglyceryl esters, with long chain n-alkyl esters, preferably C12-C22, are preferred.

[0022] Of course, all the listed acids and derivatives are pharmaceutical acceptable or physiologically applicable derivatives. In addition, the present invention also relates to pharmaceutically acceptable compounds derived therefrom. Moreover, the present invention relates to pharmaceutically acceptable salts of the phytanic acid and / or phytanic acid or derivatives thereof, e.g., alkali metal, alkaline-earth metal, ammonium and alkylammonium salts such as a Na, K, Mg, Ca, or tetramethylammonium salt, or pharmaceutically acceptable solvates thereof. Suitable pharmaceutically acceptable salts include acid addition salts. Suitable acid addition salts include pharmaceutically acceptable inorganic salts such as sulfates, nitrates, phosphates, borates, hydrochlorides, and hydrobromides and pharmaceutically acceptable organic acid addition salts such as acetates, tartrate maleates, citrates, succinates, benzoates, ascorbates, menthane-sulphonates, alpha keto glutarates, and alpha-glycerophosphates. Suitable pharmaceutically acceptable solvates include hydrates.

[0023] As used herein the term "pharmaceutically acceptable" or "physiologically applicable" means compounds, compositions, and ingredients for both human and veterinary (for example swine, bovine, chicken, and turkey) use, administering in an effective pharmaceutical amount in a human or animal.

[0024] Diabetics often suffer from a complete derangement of the entire metabolic condition characterized by hyperlipidaemia, increase in cholesterol (hypercholesterinaemia, hypertriglycerinaemia), hypertension, obesity, and hyperinsulinaemia, a clinical entity which is referred to as metabolic syndrome or syndrome X and leads to a very wide range of late complications. Apart from decreasing hyperinsulinaemia, phytanic acid and / or phytanic acid or derivatives thereof also decrease triglycerides, cholesterol, and fibrinogen and are thus excellently suitable for treating the metabolic syndrome. Therefore, phytanic acid and / or phytanic acid or derivatives thereof are also useful for the treatment or prevention of such conditions associated with diabetes mellitus. In this context, the present invention embraces especially the treatment or prevention of the so-called impaired glucose tolerance and related obesity.

[0025] In a further embodiment of the present invention phytanic acid derivatives are also useful to accompany or to support insulin therapy in combination with known active compounds.

[0026] In the above mentioned treatments or prevention, the phytanic acid derivatives may be administered *per se* or, preferably, as a pharmaceutical composition also contains a pharmaceutically acceptable carrier.

[0027] Accordingly, the present invention also provides a pharmaceutical composition for the treatment or prevention of Type II diabetes mellitus, which composition contains phytanic acid derivatives and a pharmaceutically acceptable carrier therefor.

[0028] The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use. Usually the pharmaceutical compositions of the present invention will be adapted for oral or parenteral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged. Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used. In accordance with conventional pharmaceutical practice the carrier may contain a diluent, filler, disintegrate, wetting agent, lubricant, colorant, flavorant, and / or other conventional adjuvants. Typical carriers include, for example, icrocystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, sodium lauryl sulfate, or sucrose.

[0029] Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 mg, more usually 0.1 to 500 mg, and more especially 0.1 to 100 mg. Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention. In the above mentioned treatments the phytanic acid derivatives, may be taken in doses such as those described above, one to six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg, generally about 0.5 to 10 mg. The daily dose of the active compound is usually 0.1 to 50 mg/kg body

weight. Usually 0.5 to 40 mg/kg/day and preferably 1.0 to 20 mg/kg/day are effective in one or several administrations per day in order to obtain the desired results. Of course, the administered dose depends on the age, state of health, and weight of the recipient, the extent of the disease, the type of additional treatments that may be carried out at the same time, and the type of desired effect.

5 [0030] In a preferred embodiment phytanic acid derivatives, preferably phytanic acid as such, is/are administrated to a human or animal, whereby potential target cells, such as liver cells, are exposed to a concentration of 10 to 100 µM therein.

[0031] No unacceptable toxicological effects are observed when the active compounds are administered in accordance with the above mentioned invention.

10 [0032] A further preferred embodiment of the present invention is a dietary supplement, which may also be referred to as a nutraceutical composition for the prevention of non-insulin dependent diabetes mellitus, wherein the composition comprises phytanic acid derivatives as food or feed additives or ingredients and further additives and / or adjuvants.

[0033] Some of the most important results of the present invention are summarized in the Figures.

15 [0034] Figure 1. Effect of phytanic acid on cell viability. Rat primary hepatocytes were cultured in media containing various amounts of phytanic acid for 24 h at 37°C. Subsequently cell viability was determined using the neutral red uptake assay. Data is presented as means ± SD of 3 independent experiments.

[0035] Figure 2. Glucose uptake in hepatocytes. Rat primary hepatocytes were cultured for 24 h at 37°C in media containing phytanic acid 10 µM (□) and 100 µM (■), palmitic acid 100 µM (●), DHA 100 µM (○), and control (▲). Subsequently [³H]-2-deoxy-D-glucose uptake was measured after 15, 30 and 60 min incubation periods. Data is presented as means ± SD of 3 independent experiments.

20 [0036] Figure 3. mRNA levels for GLUT-1 (○), GLUT-2 (◊), glucokinase (Δ), and PEPCK (□) were determined with the TaqMan™ at different time points after stimulation of the rat primary hepatocytes with 100 µM phytanic acid. mRNA levels were normalized to β-actin expression and expressed relative to untreated cells. The data is presented as means of 3 independent experiments. Error bars were calculated as described in Example 3.

25 [0037] Figure 4. mRNA levels for GLUT-1, GLUT-2, glucokinase, and PEPCK were determined with the TaqMan™ methodology after a 24 h stimulation of the rat primary hepatocytes with 100 µM phytanic acid, palmitic acid, and DHA. mRNA levels were normalized to β-actin expression and expressed relative to untreated cells. The data is presented as means of 3 independent experiments. Error bars were calculated as described in Example 3.

30 [0038] Figure 5. mRNA levels for ApoA1, ApoE, Cyp7a, Cyp4a1, HMG-CoA reductase LCAT, LDLR, LFABP, LPL, and TNFα. The mRNA levels were determined with the TaqMan™ methodology after a 24 h stimulation of the rat primary hepatocytes with 10 µM phytanic acid, palmitic acid, and DHA. mRNA levels were normalized to β-actin expression and expressed relative to untreated cells. The data is presented as means of 3 independent experiments. Error bars were calculated as described in Example 3.

35 [0039] Figure 6. Precursors and metabolite of phytanic acid. Metabolism proceeds from phytol to phytanic acid through phytenic acid.

[0040] Figure 7. Plasma insulin concentrations after the administration of 150 mg phytanic acid / kg feed (P-10, shaded bars) and 750 mg phytanic acid / kg feed (P-50, closed bars), respectively or control chow (control, open bars). Male Wistar rats were adapted for two days and then fed with the respective substance. The values are means ± SD (see Example 4).

40 [0041] The following examples serve to explain the invention in greater detail, without the latter being restricted to products and embodiments described in the examples.

Examples

45 Materials

[0042] Ham F12 cell culture medium and the fatty acid free artificial serum supplement BMS were purchased from Life Technologies Inc., Gaithersburg, MD and Biochrom KG, Berlin, Germany, respectively. Phytanic acid, palmitic acid, DHA, and neutral red were obtained from Sigma-Aldrich Co, Buchs, Switzerland. PCR-primers were purchased from Life Technologies Inc., Gaithersburg, MD and TaqMan™-probes from Integrated DNA Technologies, Inc., Coralville IA.

Cell culture

55 [0043] Primary rat hepatocytes were obtained as previously described (Goldlin, C. R. & Boelsterli, U. A. (1991) Reactive oxygen species and non-peroxidative mechanisms of cocaine-induced cytotoxicity in rat hepatocyte cultures, Toxicology, 69, 79-91). Cells were cultured in 6-well plates in a fatty acid free medium (Ham F12 supplemented with 10% BMS) at 37°C in a humidified atmosphere containing 5% CO₂; and stimulated in a time and dose dependent manner with phytanic acid, palmitic acid or DHA.

Example 1. Cell viability

[0044] Viability of cells cultivated under the above conditions was determined by neutral red uptake assay (Maria C. Martinez-Diez, Maria A. Serrano, Maria J. Monte, Jose J.G. Marin, Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture, *Biochimica et Biophysica Acta* 1500 (2000) 153-160). In brief, a final Neutral red concentration of 50 µg/ml in sterile PBS was used. This solution was prewarmed to 37°C before its use. The cells were washed once with PBS to remove non-adherent and dead cells. This was replaced by Neutral red-containing medium. The cultures were incubated for 3h at 37°C in an atmosphere of 5% CO₂, 95% air allowing the lysosomes and Golgi apparatus of viable cells to take up the dye. The cultures were then carefully washed with Neutral red-free PBS to eliminate remaining extracellular dye. The incorporated Neutral red was eluted from the hepatocytes with 50% ethanol supplemented with 1% acetic acid for 10 min. Absorbance at 535 nm of the eluate was measured.

[0045] The effect of various phytanic acid concentrations on cell viability was measured with the neutral red uptake assay (Figure 1). Incubation of the hepatocytes for 24 h with up to 100 µM phytanic acid showed no effect on cell viability. At the concentration of 1 mM phytanic acid only 54 ± 17 % of the cells survived compared to untreated.

Example 2. 2-deoxy-D-glucose uptake

[0046] Cells cultured in 24-well plates were treated for 24 h with phytanic acid, palmitic acid, and DHA. Subsequently the medium was removed and cells were washed twice with pre-warmed phosphate buffered saline, pH 7.4 (PBS). 500 µl of pre-warmed glucose reaction mixture (0.01 mM 2-deoxy-D-glucose and 3 µCi/ml [3H]-2-deoxy-D-glucose in PBS) was then added to the cells. The reaction mixture was further incubated at 37°C for different time intervals. The reaction was terminated by aspirating the reaction mixture and washing the cells twice with ice cold 10 mM 2-deoxy-D-glucose in PBS. Cells were then solubilized with 500 µl of 1% sodium dodecyl sulfate, 400 µl of which was transferred to scintillation vials containing 5 ml Quickszint 1 (Zinsser Analytic, Frankfurt, Germany). Radioactivity was counted in a Tri-Carb 2500 (Packard, Meriden, CT) liquid scintillation counter. The remaining lysate was used for protein content determination with the BCA Protein Assay Reagent Kit (Pierce, Rockford, IL). Data are expressed as means ± SD from 3 independent experiments.

[0047] Measurement of 2-deoxy-D-glucose uptake in primary rat hepatocytes cultures during the time course of study, revealed a substantial increase of 2-deoxy-D-glucose uptake in hepatocytes treated with 100 µM phytanic acid as compared with the control, palmitic acid or DHA (Figure 2). In cells treated with phytanic acid at concentrations lower than 100 µM no measurable effect on 2-deoxy-D-glucose uptake was observed.

Example 3. Quantitative RT-PCR: mRNA expression in response to phytanic acid

[0048] For the quantification of the mRNA expression levels, Real Time Quantitative TaqMan™ PCR using the multiplex method was employed as follows. Total RNA was isolated using the RNeasy kit from QIAGEN (Valencia, CA). The first strand cDNA was synthesized in a 20 µl reaction from 5 µg total RNA by reverse transcription with the SuperScriptIII™ Reverse Transcriptase Kit (Life Technologies Inc., Coralville IA) and 100 ng random hexamers, as previously described (Zimmermann, U., Fluehmann, B., Born, W., Fischer, J. A. & Muff, R. (1997) Coexistence of Novel Amylin-Binding Sites With Calcitonin Receptors in Human Breast Carcinoma Mcf-7 Cells, *Journal of Endocrinology*, 155, 423-431). Subsequently the cDNA was diluted to 500 µl. In a 50 µl reaction, 10 µl cDNA was amplified in the 7700 Sequence Detector (PE Biosystems, Foster City, CA), using the Universal Master Mix (PE Biosystems, Foster City, CA) and the following PCR-primers and TaqMan™-probes at the concentrations of 300 nM and 100 nM, respectively, and PCR-primers and TaqMan™-probes for the reference gene β-actin at concentration of 50 nM. The sequences of PCR-primers and TaqMan™-probes are shown in Table 1.

TABLE 1

5 Sequence of PCR-primers and TaqMan™-probes used in the amplification
of cDNA of GLUT-1 (G-1), GLUT-2 (G-2), glucokinase (glu), PEPCK
(PEP), ApoA1 (ApA1), ApoE (ApE), Cyp7a (C7a), Cyp4a1 (C4a1), HMG-
10 CoA reductase (HMG), LCAT, LDLR, LFABP (LFA), LPL, TNF α , and β -
actin (act)

15 G-1/p1: GGTCATCATCAGCATGGAGTTC (SEQ ID NO: 1)

G-1/p2: GGGCATGATTGGTCCCTCTC (SEQ ID NO: 2)

20 G-1/taq: FAM-CCTGCCAAAGCGATTAACAAAGAGGCC-Tamra (SEQ ID
NO: 3)

25 G-2/p1: CGCCCTCTGCTTCCAGTACA (SEQ ID NO: 4)

30

35

40

45

50

55

G-2/p2: AGGACCACCCAGCAAAAA (SEQ ID NO: 5)

5 G-2/taq: FAM-CGGACTTCCTCGGGCCTACGTGT-Tamra (SEQ ID NO:
6)

10 glu/p1: CGTGGATGGCTCCGTGTAC (SEQ ID NO: 7)

glu/p2: TGTCAGCCTGCGCACACT (SEQ ID NO: 8)

15 glu/taq: FAM-AGCTGCACCCGAGCTTCAAGGAGC-Tamra (SEQ ID NO: 9)

PEP/p1: CGCTGGATGTCAGAAGAGGAC (SEQ ID NO: 10)

20 PEP/p2: ACATGGTGCAGCCTTTCAT (SEQ ID NO: 11)

PEP/taq: FAM-AAAGCATTCAACGCCAGGTTCCCG-Tamra (SEQ ID NO:
12)

25 ApA1/p1: GCCACTGTGTATGTGGATGCA (SEQ ID NO: 13)

ApA1/p2: TTGCCCAAAGTGGAGGATTC (SEQ ID NO: 14)

30 ApA1/taq: FAM-ACAGCGGCAGAGACTATGTGTCCCAGTT-Tamra (SEQ
ID NO: 15)

ApE/p1: GGTCCAGGAAGAGCTGCAGA (SEQ ID NO: 16)

35 ApE/p2: CCGTCATAGTGTCCATCAG (SEQ ID NO: 17)

ApE/taq: FAM-CTCCAAGTCACACAGGAAC TGACGGT-Tamra (SEQ ID
NO: 18)

40 C7a/p1: GACTGGAAAAAATTCATTACACTACTTCT (SEQ ID NO: 19)

45 C7a/p2: CGTGGTATTCATCATTGGG (SEQ ID NO: 20)

C7a/taq: FAM-CGAAGGCATTGGACACAGAACATTG-Tamra (SEQ ID
NO: 21)

50 C4a1/p1: GCAGTTCCCATCACCTCCCT (SEQ ID NO: 22)

C4a1/p2: TGCTGTAGTTCTTGTCACCTTGAA (SEQ ID NO: 23)

5' C4a1/taq: FAM-CCACTGGTTCTTGGGCACAAGCA-Tamra (SEQ ID NO:
24)

5 HMG/p1: TGGCTGGTGAGTTGTCCCTG (SEQ ID NO: 25)

HMG/p2: TTATCTTGATCTGTTGTGAACCATG (SEQ ID NO: 26)

10 HMG/taq: FAM-ATGTCCTGCTGCCAATGCTGCCA-Tamra (SEQ ID NO:
27)

15 LCAT/p1: CATGCGGATCCTGGCCT (SEQ ID NO: 28)

LCAT/p2: TCTCTCAGCTTATGTTGGACATGA (SEQ ID NO: 29)

20 LCAT/taq: FAM-AGGTGACAACCAGGGCATCCG-Tamra (SEQ ID NO:
30)

LDLR/p1: GGTGGTCAGCAGCCCC (SEQ ID NO: 31)

25 LDLR/p2: CAGCTGCGATGGATACTCA (SEQ ID NO: 32)

30 LDLR/taq: FAM-CCTCCCTCGAGTTCCACTGTGGCAGTA-Tamra (SEQ ID
NO: 33)

LFA/p1: CAAGGTGATCCACAATGAGTTCA (SEQ ID NO: 34)

35 LFA/p2: GACCTTTCCCCAGTCATGGT (SEQ ID NO: 35)

LFA/taq: FAM-TGGGGGAGGAGTGCAGACTGGAGA-Tamra (SEQ ID NO:
36)

40 LPL/p1: TCGGGCCCAGCAACTT (SEQ ID NO: 37)

LPL/p2: GGCCACATCATTCCCACC (SEQ ID NO: 38)

45 LPL/taq: FAM-TCCAGTGTCTGCCGGCTATACCAAGC-Tamra (SEQ ID
NO: 39)

50 TNF α /p1: TCGTAGGTCAAACCACCAAGC (SEQ ID NO: 40)

TNF α /p2: TATTGGCCAGGAGGGCGT (SEQ ID NO: 41)

TNF α /taq: FAM-AGGAGCAGCTGGAGTGGCTGAGCCAG-Tamra (SEQ ID NO: 42)

5

act/p1: GACAGGATGCAGAGGAGATTACTG (SEQ ID NO: 43)

10

act/p2: CCACCGATCCACACAGAGTACTT (SEQ ID NO: 44)

15

act/taq: VIC-TCAAGATCATTGCTCCTCCTGAGCGC-Tamra (SEQ ID NO: 45)

15

[0049] The induction of gene expression, and corresponding error bars in the figures were calculated from 3 independent experiments using the $\Delta\Delta$ Ct method according to the manufacturer's protocol.

[0050] mRNA levels of the reference genes encoding for β -actin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), hypoxanthine ribosyl transferase (HPRT), and 18S ribosomal RNA were compared in cells treated for 24 h with or without 100 μ M phytanic acid. mRNA levels of β -actin and 18S ribosomal RNA were not affected by phytanic acid (not shown). Therefore, all results were normalized to β -actin mRNA levels. Measurement of mRNA levels for GLUT-1 and PEPCK in response to 100 μ M phytanic acid revealed after 6 hours a maximal 5.6 (5.1-6.2)-fold and 4.4 (3.4-5.7)-fold induction, respectively (Figure 3). mRNA levels of GLUT-2 and glucokinase were found to be maximal after a 24-h stimulation period with phytanic acid. A 2.2 (1.6-2.9)-fold and 2.4 (1.7-3.3)-fold induction of mRNA levels for GLUT-1 was observed in hepatocytes stimulated for 24 h with 100 μ M phytanic acid and palmitic acid, respectively (Figure 4). Lower phytanic acid and palmitic acid concentrations as well as DHA concentrations up to 100 μ M did not affect GLUT-1 mRNA levels. Treatment of the cells for 24 h with phytanic acid (0.01-100 μ M) induced mRNA levels for GLUT-2 at least 2-fold, with a maximal induction of 3.2 (2.7-3.8)-fold (100 μ M) (Figure 4). However, at low palmitic acid concentrations a minor induction of GLUT-2 mRNA levels was observed. In comparison, DHA did not affect GLUT-2 mRNA levels. mRNA levels of glucokinase and PEPCK were induced by 100 μ M phytanic acid 3.0 (2.5-3.4)-fold and 2.5 (1.7-3.6)-fold. The transcription of glucokinase as well as PEPCK mRNA was reduced by 100 μ M palmitic acid and DHA. After phytanic acid treatment (10 μ M for 24 h) we observed an increase for the transcripts of cytochrome P450/4A1 (Cyp4a1), 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)-reductase, lipoprotein lipase (LPL), low-density lipoprotein receptor (LDLR), PEPCK, and tumor necrosis factor α (TNF α). In contrast, the mRNAs encoding for apolipoprotein A1 (ApoA1) and apolipoprotein E (ApoE) were downregulated by phytanic acid. mRNA levels for liver fatty acid binding protein (LFABP), cholesterol 7 α -hydroxylase and glucokinase (Cyp7a) remained unaffected (Figure 5).

Example 4. *In vivo* study on the efficacy of phytanic acid

[0051] To determine the beneficial effect of phytanic acid on plasma insulin levels, a study was performed using male Wistar rats. The animals were adapted for two days and then fed with control chow, 150 mg phytanic acid / kg feed (P-10), and 750 mg phytanic acid / kg feed (P-50), respectively. Blood samples were taken at day 7 and the insulin concentration in the plasma (Figure 7). The application of different concentrations of phytanic acid could reduce the plasma insulin.

45

Abbreviations

[0052] In the present invention, the following abbreviations are used: Apolipoprotein A1 (ApoA1) and Apolipoprotein E (ApoE), cytochrome P450/4A1 (Cyp4a1), cholesterol 7 α -hydroxylase and glucokinase (Cyp7a), docohexaenoic acid (DHA), facilitative glucose transporter (GLUT), 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)-reductase, lipoprotein lipase (LPL), low-density lipoprotein receptor (LDLR), liver fatty acid binding protein (LFABP), phosphoenolpyruvate carboxykinase (PEPCK), peroxisome proliferator-activated receptor (PPAR), PPAR responsive element (PPRE), all-trans-retinoic acid receptor (RAR), 9-cis-retinoic acid receptor (RXR), tumor necrosis factor α (TNF α)

55

5 <212> DNA
<213> Rat primary hepatocytes

10 <400> 4
cgccctctgc ttccagtcaca

15 <210> 5
<211> 19
<212> DNA
<213> Rat primary hepatocytes

20 <400> 5
aggaccaccc cagcaaaaa

25 <210> 6
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> TagMan-probe for amplification of GLUT-2 cDNA of rat primary hepatocytes

30 <220>
<221> modified_base
<222> (1)..(1;
<223> 6-carboxy-fluoresceine-cytosine

<220>
<221> modified_base
<222> (24)..(24)
<223> 6-carboxy-tetramethyl-rhodamine-thymine

35 <400> 6
cggacttctt cgggccttac gtgt

40 <210> 7
<211> 19
<212> DNA
<213> Rat primary hepatocytes

45 <400> 7
cgtggatggc tcctgttac

50 <210> 8
<211> 18
<212> DNA
<213> Rat primary hepatocytes

55 <400> 8
tgtcagctg cgcacact

60 <210> 9
<211> 24
<212> DNA
<213> Artificial Sequence
<220>

5 <223> TaqMan-probe for amplification of glucokinase cDNA of rat primary hepatocytes

10 <220>
<221> modified_base
<222> (1)..(1)
<223> 6-carboxy-fluoresceine-adenine

15 <220>
<221> modified_base
<222> (24)..(24)
<223> 6-carboxy-tetramethyl-rhodamin-cytosine

20 <400> 9
agctgcaccc gagcttcaag gagc 24

25 <210> 10
<211> 21
<212> DNA
<213> Rat primary hepatocytes

30 <400> 10
cgctggatgt cagaagagga c 21

35 <210> 11
<211> 19
<212> DNA
<213> Rat primary hepatocytes

40 <400> 11
acatggtgcg gcctttcat 19

45 <210> 12
<211> 24
<212> DNA
<213> Artificial Sequence

50 <220>
<221> modified_base
<222> (1)..(1)
<223> 6-carboxy-fluoresceine-adenine

55 <220>
<221> modified_base
<222> (24)..(24)
<223> 6-carboxy-tetramethyl-rhodamin-guanine

60 <400> 12
aaagcattca acgccagggtt cccg 24

65 <210> 13
<211> 21
<212> DNA
<213> Rat primary hepatocytes

5 <400> 13
 gccactgtgt atgtggatgc a 21

 10 <210> 14
 <211> 20
 <212> DNA
 <213> Rat primary hepatocytes

 15 <400> 14
 ttgccccaaag tggaggattc 20

 20 <210> 15
 <211> 29
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> TaqMan-probe for amplification of ApoA1 cDNA cf rat primary
 hepatocytes

 25 <220>
 <221> modified_base
 <222> (1)..(1)
 <223> 6-carboxy-fluoresceine-adenine

 30 <400> 15
 acagcgccag agactatgtg tcccagttt 29

 35 <210> 16
 <211> 20
 <212> DNA
 <213> Rat primary hepatocytes

 40 <400> 16
 ggtccaggaa gagctgcaga 20

 45 <210> 17
 <211> 22
 <212> DNA
 <213> Rat primary hepatocytes

 50 <400> 17
 ccgtcatagt gtcctccatc ag 22

 55 <210> 18
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> TaqMan-probe for amplification of ApoE cDNA cf rat primary
 hepatocytes

5 <220>
<221> modified_base
<222> (1)...(1)
<223> 6-carboxy-fluoresceine-cytosine

10 <220>
<221> modified_base
<222> (27)...(27)
<223> 6-carboxy-tetramethyl-rhodamin-thymine

15 <400> 18
ctcccaagtc acacaggaac tgacggt 27

20 <210> 19
<211> 30
<212> DNA
<213> Rat primary hepatocytes

25 <400> 19
gactggaaaa aatttcattta cactacttct 30

30 <210> 20
<211> 22
<212> DNA
<213> Rat primary hepatocytes

35 <400> 20
cgtqqtattt ccatcatttg qq 22

40 <210> 21
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> TaqMan-probe for amplification of Cyp7a cDNA cf rat primary hepatocytes

45 <220>
<221> modified_base
<222> (1)...(1)
<223> 6-carboxy-fluoresceine-cytosine

50 <220>
<221> modified_base
<222> (27)...(27)
<223> 6-carboxy-tetramethyl-rhodamin-guanine

55 <400> 21
cgaaggcatt tggacacaga agcattg 27

56 <210> 22
<211> 20
<212> DNA
<213> Rat primary hepatocytes

57 <400> 22

	gcagttccca tcacctccct	20
5	<210> 23 <211> 25 <212> DNA <213> Rat primary hepatocytes	
10	<400> 23 tgctgttagtt ctttgtcacc ttgaa	25
15	<210> 24 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> TaqMan-probe for amplification of Cyp4al cDNA of rat primary hepatocytes	
20	<220> <221> modified_base <222> (1)..(1) <223> 6-carboxy-fluoresceine-cytosine	
25	<220> <221> modified_base <222> (24)..(24) <223> 6-carboxy-tetramethyl-rhodamin-adenine	
30	<400> 24 ccactggttc tttgggcaca agca	24
35	<210> 25 <211> 20 <212> DNA <213> Rat primary hepatocytes <400> 25 tggctggta gttgtccttg	20
40	<210> 26 <211> 26 <212> DNA <213> Rat primary hepatocytes	
45	<400> 26 ttatctttqa tctgttgta accatg	26
50	<210> 27 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> TaqMan-probe for amplification of HMG-CoA reductase cDNA of rat primary hepatocytes	
55	<220>	

<221> modified_base		
<222> (1)..(1)		
<223> 6-carboxy-fluoresceine-adenine		
5 <220>		
<221> modified_base		
<222> (23)..(23)		
<223> 6-carboxy-tetramethyl-rhodamin-adenine		
10 <400> 27		23
atgtcctgct gccaatgcgt cca		
<210> 28		
<211> 17		
15 <212> DNA		
<213> Rat primary hepatocytes		
<400> 28		17
catggggatc ctggccct		
20 <210> 29		
<211> 25		
<212> DNA		
<213> Rat primary hepatocytes		
25 <400> 29		25
tctctcagct ttatgttgaa catga		
<210> 30		
<211> 22		
30 <212> DNA		
<213> Artificial Sequence		
<220>		
<223> TaqMan-probe for amplification of LCAT cDNA of rat primary hepatocytes		
35 <220>		
<221> modified_base<222> (1)..(1)		
<223> 6-carboxy-fluoresceine-adenine		
<220>		
40 <221> modified_base		
<222> (22)..(22)		
<223> 6-carboxy-tetramethyl-rhodamin-guanine		
<400> 30		22
45 aggtgacaac cagggcatcc cg		
<210> 31		
<211> 17		
<212> DNA		
50 <213> Rat primary hepatocytes		
<400> 31		17
ggtgttcagc agccccct		

5 <210> 32
<211> 21
<212> DNA
<213> Rat primary hepatocytes

10 <400> 32
cagctgcatat ggatacacat a

15 <210> 33
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<223> TaqMan-probe for amplification of LDLR cDNA of rat primary hepatocytes

20 <220>
<221> modified_base
<222> (1)..(1)
<223> 6-carboxy-fluoresceine-cytosine

25 <220>
<221> modified_base
<222> (27)..(27)
<223> 6-carboxy-tetramethyl-rhodamin-adenine

30 <400> 33
cctccctcgaa gttccactgt ggcagta

35 <210> 34
<211> 23
<212> DNA
<213> Rat primary hepatocytes

40 <400> 34
caagggtgtatc cacaatgagt tca

45 <210> 35
<211> 21
<212> DNA
<213> Rat primary hepatocytes

50 <400> 35
gaccttttcc ccagtcattgg t

55 <210> 36
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<223> TaqMan-probe for amplification of LFAPP cDNA of rat primary hepatocytes

60 <220>
<221> modified_base
<222> (1)..(1)
<223> 6-carboxy-fluoresceine-thymine

5 <220>
<221> modified_base
<222> (24)..(24)
<223> 6-carboxy-tetramethyl-rhodamin-adenine

10 <400> 36
tgggggagga gtgcgaaactg gaga 24

15 <210> 37
<211> 16
<212> DNA
<213> Rat primary hepatocytes

20 <400> 37
tcgggcccaag caactt 16

25 <210> 38
<211> 19
<212> DNA
<213> Rat primary hepatocytes

30 <400> 38
ggccacatca tttcccacc 19

35 <210> 39
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<221> modified_base
<222> (1)..(1)
<223> 6-carboxy-fluoresceine-thymine

40 <220>
<221> modified_base
<222> (26)..(26)
<223> 6-carboxy-tetramethyl-rhodamin-cytosine

45 <400> 39
tccagtgtct gccggctata ccaagc 26

50 <210> 40
<211> 21
<212> DNA
<213> Rat primary hepatocytes

55 <400> 40
tcgttaggtca aaccaccaag c 21

<210> 41
<211> 18

	<212> DNA	
	<213> Rat primary hepatocytes	
5	<400> 41	18
	tattggccag gagggcgt	
	<210> 42	
	<211> 26	
10	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> TagMan-probe for amplification of TNFalpha cDNA of rat primary hepatocytes	
15	<220>	
	<221> modified_base	
	<222> (1)...(1)	
	<223> 6-carboxy-fluoresceine-adenine	
20	<220>	
	<221> modified_base	
	<222> (26)...(26)	
	<223> 6-carboxy-tetramethyl-rhodamin-guanosine	
	<400> 42	
25	aggagcagct ggagtggctg agccag	26
	<210> 43	
	<211> 24	
	<212> DNA	
30	<213> Rat primary hepatocytes	
	<400> 43	
	gacaggatgc agaggagatt actg	24
35	<210> 44	
	<211> 23	
	<212> DNA	
	<213> Rat primary hepatocytes	
40	<400> 44	
	ccaccgatcc acacagagta ctt	23
	<210> 45	
	<211> 26	
45	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> TagMan-probe for amplification of beta-actin cDNA of rat primary hepatocytes	
50	<220>	
	<221> modified_base	
	<222> (1)...(1)	
	<223> VIC-thymine	
	VIC: unknown structure	
55		

<220>
 <221> modified base
 <222> (26)..(26)
 5 <223> 6-carboxy-tetramethyl-rhodamin-cytosine

 <400> 45
 tcaagatcat tgctcctctt gagcgc

26

10

Claims

15 1. A process for the preparation of a product for the treatment or prevention of a disease selected from the group consisting of non-insulin dependent diabetes mellitus, syndrome X, hyperlipidaemia, hypertension, hyperinsulinaemia, hypercholesterinaemia, hypertriglycerinaemia, impaired glucose tolerance and related obesity comprising combining phytanic acid or derivatives thereof with a pharmaceutically acceptable carrier.

20 2. A composition for the treatment or prevention of non-insulin dependent diabetes mellitus comprising phytanic acid or derivatives thereof.

25 3. A composition according to claim 2 further comprising a pharmaceutically acceptable carrier selected from the group consisting of diluent, filler, disintigrant, wetting agent, lubricant, colorant, flavorant, adjuvants, and combinations thereof.

30 4. A composition according to claim 2 or 3, comprising phytanic acid or derivatives thereof in an amount of 0.1 to 1000 mg, preferably 0.1 to 500 mg.

35 5. A dietary supplement comprising a composition according to claim 2.

6. Use of phytanic acid or phytenic acid or derivatives or precursors thereof as pharmaceutical compounds or supplements to food or feed for the treatment or prevention of non-insulin dependent diabetes mellitus in humans or animals.

40 7. Use according to claim 6, wherein the said derivatives or precursors are selected from the group consisting of phytol, hydroxy-phytanic acid, phytanic esters, phytanic amides, hydroxy-phytanic esters, hydroxy phytanic amides, hydroxy-phytenic acid, phytenic esters, phytenic amides, hydroxy-phytenic esters, and hydroxy-phytenic amides.

45 8. Use according to claims 6 or 7, wherein said derivatives or precursors have the activity of a modulator for inducing the genes of the glucose transporter family to increase cellular glucose uptake.

9. Use according to claim 8, wherein the said genes are selected from the group consisting of GLUT-1, GLUT-2, GLUT-4 and glucokinase.

50 10. A method for the treatment or prevention of diabetes mellitus and conditions associated with diabetes mellitus in a human or animal, comprising administering to a human or an animal an effective dose of a pharmaceutical composition or a dietary supplement comprising phytanic acid, a phytanic acid precursor, or a derivative of phytanic acid.

11. A method according to claim 10, wherein said derivatives or precursors derive from phytanic acid or phytenic acid.

55 12. A method according to claim 11, wherein said derivatives and precursors are selected from the group consisting of phytol, hydroxy-phytanic acid, phytanic esters, phytanic amides, hydroxy-phytanic esters, hydroxy-phytanic amides, hydroxy-phytenic acid, phytenic esters, phytenic amides, hydroxy-phytenic esters, and hydroxy-phytenic amides, and combinations thereof.

13. A method for increasing cellular glucose uptake comprising administering to an animal or a human in need of increased cellular glucose uptake a phytanic acid derivative or a phytanic acid precursor in an effective amount to increase cellular glucose uptake.
- 5 14. A method according to claim 13 wherein the effective amount of the phytanic acid derivative or phytanic acid precursor induces a gene selected from the group consisting of GLUT-1, GLUT-2, GLUT-4, glucokinase, and combinations thereof to increase cellular glucose activity within the animal or human.
- 10 15. A method according to any one of claims 10 to 14, wherein the effective amount is preferably 0.1 to 50 mg/kg/day (body weight) and most preferably 1.0 to 20 mg/kg/day (body weight).

15

20

25

30

35

40

45

50

55

Figure 1




Figure 2





Figure 3


Figure 4


Figure 5

Figure 6





Figure 7



THIS PAGE BLANK (USPTO)

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11)



EP 1 177 789 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
29.01.2003 Bulletin 2003/05

(51) Int Cl.7: A61K 31/20, A61P 3/04,
A61P 3/06, A61P 3/10

(43) Date of publication A2:
06.02.2002 Bulletin 2002/06

(21) Application number: 01118230.0

(22) Date of filing: 30.07.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 04.08.2000 EP 00116848

(71) Applicant: Roche Vitamins AG
4070 Basel (CH)

(72) Inventors:

- Fluehmann, Beat
8055 Zuerich (CH)

- Heim, Manuel
79098 Freiburg (DE)
- Hunziker, Willi
4312 Magden (CH)
- Weber, Peter
79429 Malsburg-Marzell (DE)

(74) Representative: Müller, Ingrid, Dr. et al
Grenzacherstrasse 124
CH-4070 Basel (CH)

(54) Use of phytanic acid for the treatment of diabetes

(57) This invention relates to a novel method for the treatment or prevention of preferably non-insulin dependent (NIDDM or so-called Type II) diabetes mellitus, syndrome X, hyperlipidaemia, hypertension, hyperinsulinaemia, hypercholesterinaemia, hypertriglycerinae-

mia, or other conditions associated with impaired glucose tolerance such as obesity, and in particular to the use of phytanic acid derivatives for the said treatment or prevention.

EP 1 177 789 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 11 8230

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)									
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim										
X	DE 196 44 422 A (FALANA ANDRE DR MED ; SCHULZ STEFAN DR (DE)) 30 April 1998 (1998-04-30) * see in particular page 2, lines 17-19 and 54-57; claims 1, 7 and 14 *	2-5	A61K31/20 A61P3/04 A61P3/06 A61P3/10									
X	VAN DEN BRANDEN C ET AL: "Phytol and peroxisome proliferation." PEDIATRIC RESEARCH. UNITED STATES MAY 1986, vol. 20, no. 5, May 1986 (1986-05), pages 411-415, XP009000629 ISSN: 0031-3998 * see in particular the abstract and the discussion *	1-5										
X	DATABASE WPI Section Ch, Week 197735 Derwent Publications Ltd., London, GB; Class B05, AN 1977-61831Y XP002222983 & JP 52 085125 A (EISAI CO LTD), 15 July 1977 (1977-07-15) * abstract *	1-5										
Y	MUKHERJEE ET AL: "Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 386, 27 March 1997 (1997-03-27), pages 407-410, XP002081440 ISSN: 0028-0836 * see in particular the abstract; figures 2-4; page 409, right column, last paragraph *	1-15										
		-/-										
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>MUNICH</td> <td>29 November 2002</td> <td>Rodriguez-Palmero, M</td> </tr> <tr> <td colspan="3"> CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p> </td> </tr> </table>				Place of search	Date of completion of the search	Examiner	MUNICH	29 November 2002	Rodriguez-Palmero, M	CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>		
Place of search	Date of completion of the search	Examiner										
MUNICH	29 November 2002	Rodriguez-Palmero, M										
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>												



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 11 8230

DOCUMENTS CONSIDERED TO BE RELEVANT					
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)		
Y	LEMOTTE P K ET AL: "PHYTANIC ACID IS A RETINOID X RECEPTOR LIGAND" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 236, no. 1, 1 February 1996 (1996-02-01), pages 328-333, XP000611594 ISSN: 0014-2956 * see in particular the abstract * ---	1-15			
P,X	MCCARTY M F: "The chlorophyll metabolite phytanic acid is a natural rexinoid: Potential for treatment and prevention of diabetes." MEDICAL HYPOTHESES, vol. 56, no. 2, February 2001 (2001-02), pages 217-219, XP009000388 ISSN: 0306-9877 * see in particular the abstract; page 217, left and right columns * -----	1-15			
TECHNICAL FIELDS SEARCHED (Int.Cl.7)					
The present search report has been drawn up for all claims					
Place of search	Date of completion of the search	Examiner			
MUNICH	29 November 2002	Rodriguez-Palmero, M			
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document					
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document					

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 8230

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-11-2002

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
DE 19644422	A	30-04-1998	DE	19644422 A1		30-04-1998
JP 52085125	A	15-07-1977	JP	1203180 C		25-04-1984
			JP	58035505 B		03-08-1983